| abstract |
The present invention relates to an inhalable dosage form for the treatment of pulmonary hypertension in a mammal (e.g., a human), said formulation comprising an angiotensin converting enzyme inhibitor, an angiotensin receptor blocker, a beta-blocker, calcium - a channel blocker or vasodilator, or any combination thereof. The formulations of the present invention may be solutions or suspensions, and are preferably suitable for spray administration. The present invention also relates to a method of treating mammals suffering from pulmonary hypertension and to said treatment kits. |